新辅助化疗VI-RADS评分用于评估肌层浸润性膀胱癌对新辅助免疫治疗的反应:多参数MRI研究
本研究回顾性分析PURE-01试验中110例肌层浸润性膀胱癌患者的220次多参数MRI,评估新辅助化疗VI-RADS(nacVI-RADS)评分及治疗后VI-RADS评分对免疫治疗反应的诊断准确性和可重复性。结果显示nacVI-RADS 3分及以上检测残留病变的敏感度67%-84%、特异度63%-96%,检测残留肌层浸润性病变的敏感度91%-98%、特异度55%-94%,读者间一致率82%。
要点
- nacVI-RADS 3分及以上检测残留肌层浸润性病变(>ypT1)的敏感度91%-98%,阴性预测值93%-98%。
- nacVI-RADS 3分及以上检测任何残留病变(>ypT0)的准确度72%-81%,检测>ypT1的准确度71%-95%。
- VI-RADS 3分及以上检测>ypT1病变的准确度80%-95%;nacVI-RADS评分读者间一致率82%。
核心结论
- nacVI-RADS评分在评估肌层浸润性膀胱癌对新辅助免疫治疗反应时显示出良好的准确性和可重复性。
研究设计与样本
- 回顾性分析PURE-01研究(NCT02736266)中2017年2月至2019年12月入组、在根治性膀胱切除术前接受免疫治疗前后多参数MRI的患者;共110例(中位年龄67岁,IQR 61-74;96例男性),220次MRI;5名读者独立采用VI-RADS和nacVI-RADS标准阅片,以最终组织病理学诊断为参考标准。
诊断标准与关键数值
- nacVI-RADS 3分及以上检测残留病变(>ypT0)的敏感度67%-84%、特异度63%-96%、阴性预测值63%-75%;检测残留肌层浸润性病变(>ypT1)的敏感度91%-98%、特异度55%-94%、阴性预测值93%-98%;nacVI-RADS准确度对≥ypT0为72%-81%,对≥ypT1为71%-95%;VI-RADS 3分及以上对≥ypT1的准确度为80%-95%;nacVI-RADS评分读者间一致率82%(Conger κ=0.62-0.65;Gwet AC1=0.65)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background An accurate method of assessing the response of muscle-invasive bladder cancer (MIBC) to neoadjuvant treatment is needed for selecting candidates for bladder-sparing strategies. Purpose To evaluate the diagnostic accuracy and reproducibility of neoadjuvant chemotherapy Vesical Imaging Reporting and Data System (nacVI-RADS) scores and posttreatment Vesical Imaging Reporting and Data System (VI-RADS) scores when assessing MIBC response to neoadjuvant immunotherapy with multiparametric MRI (mpMRI). Materials and Methods A retrospective analysis of MRI scans was conducted in patients enrolled in the PURE-01 study (NCT02736266) from February 2017 to December 2019 who underwent pre- and postimmunotherapy mpMRI before radical cystectomy. Five readers independently reviewed the scans using VI-RADS and nacVI-RADS criteria. Diagnostic accuracy was evaluated for each reader, and the final histopathologic diagnosis served as the reference standard. Interreader agreement was assessed with the percentage of agreement, Conger κ, and Gwet agreement coefficient AC1. Results A total of 110 patients (median age, 67 years [IQR: 61-74]; 96 male) with 220 MRI scans were included; 80 (73%) patients had pure urothelial carcinoma. A total of 46 of 110 (42%) patients achieved a complete pathologic response. The sensitivity, specificity, and negative predictive value of nacVI-RADS 3 or higher for detecting residual disease (higher than stage ypT0) at radical cystectomy were 67%-84%, 63%-96%, and 63%-75%, respectively; for residual muscle-invasive disease (higher than stage ypT1), these values were 91%-98%, 55%-94%, and 93%-98%, respectively. The accuracy of nacVI-RADS was 72%-81% for stage ypT0 or higher disease and 71%-95% for stage ypT1 or higher disease. The accuracy of VI-RADS 3 or higher was 80%-95% for stage ypT1 or higher disease. The percentage of agreement for nacVI-RADS scores was 82% (κ = 0.62-0.65; AC1 = 0.65). Conclusion The nacVI-RADS scores showed good accuracy and reproducibility when assessing MIBC response to neoadjuvant immunotherapy. © RSNA, 2024 Supplemental material is available for this article.
引用
- Brembilla G, Basile G, Cosenza M, et al. Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI. Radiology. 2024. PMID: 39718497. doi:10.1148/radiol.233020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。